AAS
NVCR icon

Avantax Advisory Services’s NovoCure NVCR Stock Holding History

Avantax Advisory Services’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,984
Closed -$332K – 1211
2020
Q3 		$332K Buy
+2,984
New +$239K 0.01% 976

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Avantax Advisory Services's NVCR Position: Q4 2020 in Review

Avantax Advisory Services sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 2,984 shares — an estimated $332K sold.

Avantax Advisory Services first reported a position in NVCR in Q3 2020 and held it in 1 quarter. The position peaked at $332K in Q3 2020. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Avantax Advisory Services reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
  • Avantax Advisory Services sold 2,984 NovoCure shares in Q4 2020, an estimated $332K.
  • Avantax Advisory Services first reported a position in NovoCure in Q3 2020 and held it in 1 quarter.
  • Avantax Advisory Services's NovoCure position peaked at $332K in Q3 2020.
  • 356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Avantax Advisory Services's 13F filing for Q4 2020, filed 22 Jan 2021.